公开(公告)号：WO2022189508A1

公开(公告)日：2022-09-15

申请号：PCT/EP2022/056037

申请日：2022-03-09

Applicant: BIOINVENT INTERNATIONAL AB ,  UNIVERSITY OF SOUTHAMPTON

Inventor： FRENDÉUS, Björn ,  MÅRTENSSON, Linda ,  TEIGE, Ingrid ,  CRAGG, Mark ,  OLDHAM, Robert ,  BEERS, Stephen ,  ROGHANIAN, Ali

IPC: A61K35/00 ,  C07K16/28

Abstract: The present disclosure generally relates to antibody combinations and uses thereof.

公开(公告)号：WO2021009358A1

公开(公告)日：2021-01-21

申请号：PCT/EP2020/070319

申请日：2020-07-17

Applicant: BIOINVENT INTERNATIONAL AB ,  UNIVERSITY OF SOUTHAMPTON

Inventor： FRENDÉUS, Björn ,  TEIGE, Ingrid ,  MÅRTENSSON, Linda ,  KARLSSON, Ingrid ,  CRAGG, Mark ,  BEERS, Stephen ,  OLDHAM, Robert

IPC: A61P35/00 ,  C07K16/28 ,  A61K39/00

Abstract: Described is the combined use of a first antibody molecule that specifically binds FcyRIIb via its Fab region and that binds an Fey receptor via its Fc region, and a second antibody molecule that specifically binds PD-1 and that binds at least one Fey receptor via its Fc region, in the treatment of cancer in a patient having tumor infiltrating T lymphocytes with a medium or high PD-1 expression, as well as pharmaceutical compositions and kits comprising these two antibody molecules, and methods of treating cancer using these two antibodies. Described is also a diagnostic test for identification of patients benefitting from the treatment described herein.

公开(公告)号：WO2019138005A2

公开(公告)日：2019-07-18

申请号：PCT/EP2019/050566

申请日：2019-01-10

Applicant: BIOINVENT INTERNATIONAL AB ,  UNIVERSITY OF SOUTHAMPTON

Inventor： FRENDÉUS, Björn ,  TEIGE, Ingrid ,  MÅRTENSSON, Linda ,  CRAGG, Mark ,  BEERS, Stephen ,  ROGHANIAN, Ali ,  OLDHAM, Robert

Abstract: Described is the use of a first antibody molecule that specifically binds FcγRllb via its Fab region, but lacks Fc region or has reduced binding to Fcγ receptors via its Fc region, for use in combination with a second antibody molecule that specifically binds to a receptor present on an immune cell, wherein the immune cell is an immune cell that suppresses anti-cancer immunity, which second antibody molecule has an Fc region that binds to at least one activating Fcγ receptor, and wherein the binding of the second antibody molecule to the receptor on the immune cell causes depletion and/or deactivation of the immune cell in the treatment of an FcγRllb-negative cancer in a patient, as well as pharmaceutical compositions and kits comprising these to antibody molecules, and methods of treating cancer using these two antibodies.